Work

Targeting myeloid derived suppressor cells: Phase 0/1 trial of low dose capecitabine + bevacizumab in patients with recurrent glioblastoma.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.e13507

Authors: David M. Peereboom, Justin D. Lathia, Tyler Alban, Maksim Sinyuk, Manmeet Singh Ahluwalia, Alireza Mohammad Mohammadi, Cathy J. Brewer, Michael A. Vogelbaum

Institutions: Cleveland Clinic, Cleveland Clinic Research

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2689644968

Cites:

Cited by: 2

Related to: 10